Views: 0 Author: Site Editor Publish Time: 2026-06-30 Origin: Site
"Can ursodeoxycholic acid remove gallstones?" It’s a high-intent search query—one that reflects both patient hope and clinical reality. The short answer is yes, but only under very specific conditions.
For pharmaceutical procurement directors and formulators, however, the question isn't just about clinical efficacy. It's about sourcing pharmaceutical grade Ursodeoxycholic Acid (UDCA) that guarantees consistent dissolution rates and meets stringent global regulatory standards.
This article breaks down the science, the limitations, and why the quality of your UDCA API is the deciding factor between a successful therapy and a costly product recall.
Ursodeoxycholic Acid (often called ursodiol) doesn't "blast" stones away. Instead, it works biochemically over months:
Hydrophilic Effect: UDCA is a hydrophilic bile acid. When concentrated in the bile, it suppresses the liver's production of cholesterol and reduces the absorption of cholesterol in the intestines.
Cholesterol Saturation: It gradually desaturates bile with cholesterol, allowing the cholesterol crystals within the stones to dissolve back into the bile solution.
The API Connection: This process requires precise dosing over 6–24 months. If your Ursodeoxycholic Acid API has inconsistent potency or impurity profiles, the bile saturation levels will fluctuate, leading to treatment failure. Sourcing high purity UDCA powder ensures predictable pharmacokinetics.
Not every patient with gallstones can benefit from ursodiol for gallstones. Clinical guidelines are strict:
Stone Type: Only cholesterol gallstones (radiolucent). It does not work on pigment stones (calcium-based).
Size: Stones must be small (less than 2 cm), ideally less than 1.5 cm.
Function: The gallbladder must still be functioning (not inflamed or calcified/hardened).
Patient Profile: Typically reserved for patients who refuse surgery or have high surgical risks.
The API Connection: Because treatment takes so long, batch-to-batch consistency is non-negotiable. As a GMP UDCA manufacturer, we ensure that the crystal structure and particle size distribution remain identical across all batches, preventing variable absorption rates.
One of the most overlooked reasons for UDCA failure is API contamination. Low-grade raw materials often contain traces of Chenodeoxycholic Acid (CDCA)—a more hydrophobic, hepatotoxic bile acid.
The Risk: High levels of CDCA can cause severe diarrhea, elevated liver enzymes, and actually increase the risk of gallstone formation.
The Solution: When you buy Ursodeoxycholic Acid API, you must demand a Certificate of Analysis (CoA) showing Chenodeoxycholic Acid content < 0.2%.
Rocky Union Advantage: Our CEP certified Ursodeoxycholic Acid utilizes proprietary purification technology to keep toxic impurities at near-zero levels, ensuring maximum safety for long-term oral administration.
While gallstone dissolution is a key indication, it represents only a fraction of the market for UDCA API suppliers. Procurement teams are also focused on:
Primary Biliary Cholangitis (PBC): The only FDA-approved therapy to slow disease progression.
NAFLD/NASH: Growing off-label use for fatty liver disease.
Bile Reflux Gastritis: Protecting the stomach lining.
Cystic Fibrosis: Improving liver function in pediatric patients.
The API Connection: These therapeutic areas require different dosage forms (tablets, capsules) and often higher doses. Your Ursodeoxycholic Acid supplier must offer flexibility in bulk density and flowability to suit high-speed tablet compression or capsule filling lines.
If you are formulating UDCA for the US, EU, or Japanese markets, the question isn't just "Can it remove gallstones?" but "Can I get this approved?"
FDA/EMA Compliance: Requires full DMF (Drug Master File) support.
CEP (Certificate of Suitability): Essential for the European market to prove compliance with Ph.Eur. monographs.
Audit Readiness: With 38 years of expertise, Rocky Union provides transparent documentation trails required for GMP inspections.
When you source pharma grade UDCA, you are buying peace of mind. Non-compliant APIs lead to import alerts and shipment rejections—far more expensive than the initial cost savings of a cheap supplier.
So, can ursodeoxycholic acid remove gallstones? Yes—provided the API is pure, consistent, and compliant.
At Rocky Union, we don't just sell Ursodeoxycholic Acid powder; we provide a foundation for safe and effective hepatobiliary therapies. Our ISO & GMP certified facility ensures that every batch meets the highest standards for purity (>99.5%) and impurity control.
Ready to secure your supply chain?
Don’t gamble on quality. Partner with a leading UDCA API manufacturer that understands your regulatory hurdles.
[Contact Rocky Union] today to request a sample or our latest CoA.
Q: How long does it take for ursodiol to dissolve gallstones?
A: Typically 6 to 24 months. Consistency in the Ursodeoxycholic Acid API is crucial during this period to maintain therapeutic bile acid ratios.
Q: What is the difference between UDCA and Ursodiol?
A: They are the same compound. Ursodiol is the USAN (United States Adopted Name), while Ursodeoxycholic Acid is the INN (International Nonproprietary Name). Both refer to the active ingredient sourced from a reliable UDCA supplier.
Q: Are there side effects of rsodeoxycholic acid?
A: Rare when using high-purity API. Most side effects (like soft stools) are dose-related. However, impurities like Chenodeoxycholic Acid can cause significant hepatotoxicity.
